Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) Director Ra Capital Management, L.P. bought 2,500,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was bought at an average cost of $16.00 per share, for a total transaction of $40,000,000.00. Following the completion of the transaction, the director directly owned 5,933,787 shares in the company, valued at approximately $94,940,592. The trade was a 72.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Friday, October 30th, Ra Capital Management, L.P. bought 453,820 shares of Bambusa Therapeutics stock. The stock was purchased at an average cost of $14.63 per share, with a total value of $6,639,386.60.
Bambusa Therapeutics Price Performance
Shares of Bambusa Therapeutics stock remained flat at $16.00 on Tuesday. The stock had a trading volume of 275,809 shares, compared to its average volume of 354,454. Bambusa Therapeutics, Inc. has a fifty-two week low of $13.60 and a fifty-two week high of $17.42.
Recommended Stories
- Five stocks we like better than Bambusa Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
